Updates in the pharmacologic treatment of childhood depression

Graham J. Emslie, Taryn L. Mayes, Carroll W. Hughes

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Significant advances are being made in the treatment of depression in children and adolescents. In a relatively short period, we have moved away from whether or not children get depressed to how to develop a comprehensive treatment strategy for depression in children and adolescents. It is expected that the increase in the understanding of the psychopharmacologic management of depression in children and adolescents will be greatly enhanced by the collaborative arrangements between universities, the National Institute of Mental Health, the Food and Drug Administration, and the pharmaceutical industry. Recent changes in federal regulations have greatly enhanced the amount of research being conducted in the pediatric age group. Although research into psychopharmacologic treatment of acute depression has increased, there remain many areas in need of further research, including continuation and maintenance treatment and treatment-resistant depression. The integration of psychotherapy and psychopharmacology and the increase in effectiveness trials, which assess outcomes in addition to symptom change (such as social and family functioning and economic changes) are needed.

Original languageEnglish (US)
Pages (from-to)813-835
Number of pages23
JournalPsychiatric Clinics of North America
Volume23
Issue number4
DOIs
StatePublished - 2000

Fingerprint

Depression
Research
Treatment-Resistant Depressive Disorder
National Institute of Mental Health (U.S.)
Psychopharmacology
Drug Industry
United States Food and Drug Administration
Therapeutics
Psychotherapy
Age Groups
Economics
Pediatrics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Updates in the pharmacologic treatment of childhood depression. / Emslie, Graham J.; Mayes, Taryn L.; Hughes, Carroll W.

In: Psychiatric Clinics of North America, Vol. 23, No. 4, 2000, p. 813-835.

Research output: Contribution to journalArticle

Emslie, Graham J. ; Mayes, Taryn L. ; Hughes, Carroll W. / Updates in the pharmacologic treatment of childhood depression. In: Psychiatric Clinics of North America. 2000 ; Vol. 23, No. 4. pp. 813-835.
@article{d8ee3b40213244e8b4aee3595e4ce596,
title = "Updates in the pharmacologic treatment of childhood depression",
abstract = "Significant advances are being made in the treatment of depression in children and adolescents. In a relatively short period, we have moved away from whether or not children get depressed to how to develop a comprehensive treatment strategy for depression in children and adolescents. It is expected that the increase in the understanding of the psychopharmacologic management of depression in children and adolescents will be greatly enhanced by the collaborative arrangements between universities, the National Institute of Mental Health, the Food and Drug Administration, and the pharmaceutical industry. Recent changes in federal regulations have greatly enhanced the amount of research being conducted in the pediatric age group. Although research into psychopharmacologic treatment of acute depression has increased, there remain many areas in need of further research, including continuation and maintenance treatment and treatment-resistant depression. The integration of psychotherapy and psychopharmacology and the increase in effectiveness trials, which assess outcomes in addition to symptom change (such as social and family functioning and economic changes) are needed.",
author = "Emslie, {Graham J.} and Mayes, {Taryn L.} and Hughes, {Carroll W.}",
year = "2000",
doi = "10.1016/S0193-953X(05)70199-4",
language = "English (US)",
volume = "23",
pages = "813--835",
journal = "Psychiatric Clinics of North America",
issn = "0193-953X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Updates in the pharmacologic treatment of childhood depression

AU - Emslie, Graham J.

AU - Mayes, Taryn L.

AU - Hughes, Carroll W.

PY - 2000

Y1 - 2000

N2 - Significant advances are being made in the treatment of depression in children and adolescents. In a relatively short period, we have moved away from whether or not children get depressed to how to develop a comprehensive treatment strategy for depression in children and adolescents. It is expected that the increase in the understanding of the psychopharmacologic management of depression in children and adolescents will be greatly enhanced by the collaborative arrangements between universities, the National Institute of Mental Health, the Food and Drug Administration, and the pharmaceutical industry. Recent changes in federal regulations have greatly enhanced the amount of research being conducted in the pediatric age group. Although research into psychopharmacologic treatment of acute depression has increased, there remain many areas in need of further research, including continuation and maintenance treatment and treatment-resistant depression. The integration of psychotherapy and psychopharmacology and the increase in effectiveness trials, which assess outcomes in addition to symptom change (such as social and family functioning and economic changes) are needed.

AB - Significant advances are being made in the treatment of depression in children and adolescents. In a relatively short period, we have moved away from whether or not children get depressed to how to develop a comprehensive treatment strategy for depression in children and adolescents. It is expected that the increase in the understanding of the psychopharmacologic management of depression in children and adolescents will be greatly enhanced by the collaborative arrangements between universities, the National Institute of Mental Health, the Food and Drug Administration, and the pharmaceutical industry. Recent changes in federal regulations have greatly enhanced the amount of research being conducted in the pediatric age group. Although research into psychopharmacologic treatment of acute depression has increased, there remain many areas in need of further research, including continuation and maintenance treatment and treatment-resistant depression. The integration of psychotherapy and psychopharmacology and the increase in effectiveness trials, which assess outcomes in addition to symptom change (such as social and family functioning and economic changes) are needed.

UR - http://www.scopus.com/inward/record.url?scp=0034526287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034526287&partnerID=8YFLogxK

U2 - 10.1016/S0193-953X(05)70199-4

DO - 10.1016/S0193-953X(05)70199-4

M3 - Article

AN - SCOPUS:0034526287

VL - 23

SP - 813

EP - 835

JO - Psychiatric Clinics of North America

JF - Psychiatric Clinics of North America

SN - 0193-953X

IS - 4

ER -